Found: 26
Select item for more details and to access through your institution.
Examining the evidence for weight management in individuals with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1411, doi. 10.1111/dom.14764
- By:
- Publication type:
- Article
A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 302, doi. 10.1111/dom.14582
- By:
- Publication type:
- Article
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 10, p. 2279, doi. 10.1111/dom.14469
- By:
- Publication type:
- Article
Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 508, doi. 10.1111/dom.14244
- By:
- Publication type:
- Article
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 106, doi. 10.1111/dom.14195
- By:
- Publication type:
- Article
Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2209, doi. 10.1111/dom.14165
- By:
- Publication type:
- Article
Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 4, p. 855, doi. 10.1007/s13300-024-01542-5
- By:
- Publication type:
- Article
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 11/12, p. 1921, doi. 10.1007/s13300-022-01320-1
- By:
- Publication type:
- Article
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 10, p. 2783, doi. 10.1007/s13300-021-01140-9
- By:
- Publication type:
- Article
Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 7, p. 1437, doi. 10.1007/s13300-020-00839-5
- By:
- Publication type:
- Article
Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 6, p. 2321, doi. 10.1007/s13300-019-00709-9
- By:
- Publication type:
- Article
General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01757-z
- By:
- Publication type:
- Article
376-P: REWIND Data on Obesity and Cardiovascular (CV) Health: Waist-to-Hip Ratio (WHR) Independently Predicted CV Outcomes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-376-P
- By:
- Publication type:
- Article
982-P: Use of Antihyperglycemic Agents (AHA) with Cardioprotective Benefit in Older Patients with T2D and CVD or CV Risk Factors.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-982-P
- By:
- Publication type:
- Article
680-P: Once-Weekly Dulaglutide 3 mg and 4.5 mg Gastrointestinal Tolerability: Post-hoc Analysis of Incidence and Prevalence in Award-11.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-680-P
- By:
- Publication type:
- Article
643-P: A Model-Based Evaluation of Glycemic and Weight Changes When Switching from Semaglutide to Additional Doses of Dulaglutide.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-643-P
- By:
- Publication type:
- Article
642-P: A Model-Based Evaluation of Nausea and Vomiting Events for Additional Doses of Dulaglutide in Existing and Dulaglutide-Naïve Patients with Type 2 Diabetes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-642-P
- By:
- Publication type:
- Article
928-P: Dulaglutide Has Higher Adherence and Persistence than Semaglutide and Exenatide QW: 6-Month Follow-Up from U.S. Real-World Data.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-928-P
- By:
- Publication type:
- Article
924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-924-P
- By:
- Publication type:
- Article
233-OR: Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) vs. Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria Status: AWARD-7.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-233-OR
- By:
- Publication type:
- Article
2303-PUB: Efficacy of Dulaglutide (DU) as First Injectable Option for Patients with Type 2 Diabetes (T2D): A Post Hoc Pooled Analysis.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-2303-PUB
- By:
- Publication type:
- Article
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
- Published in:
- Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01386-4
- By:
- Publication type:
- Article
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide.
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 2, p. 215, doi. 10.1002/jcph.2373
- By:
- Publication type:
- Article
Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With Calcitriol.
- Published in:
- 2017
- By:
- Publication type:
- journal article
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article